Price$27.69-6.89 (-19.92%)
2026-02-032026-05-07
News · 26 weeks35-60%
2025-12-142026-06-07
Mix1690d
- SEC Filings8(50%)
- Leadership3(19%)
- Other2(13%)
- Earnings2(13%)
- Dividends1(6%)
Latest news
25 items- SECSEC Form 6-K filed by Galapagos NV6-K - Lakefront Biotherapeutics NV (0001421876) (Filer)
- SECSEC Form 6-K filed by Galapagos NV6-K - Lakefront Biotherapeutics NV (0001421876) (Filer)
- SECSEC Form 424B3 filed by Galapagos NV424B3 - Lakefront Biotherapeutics NV (0001421876) (Filer)
- SECSEC Form 6-K filed by Galapagos NV6-K - GALAPAGOS NV (0001421876) (Filer)
- PRGalapagos Reports First Quarter 2026 Financial Results and Provides Business UpdateGalapagos' name change to Lakefront Biotherapeutics approved at the Company's EGM ((Euronext &, NASDAQ:LKFT)Collaboration Agreement with Gilead to advance potential First and Best-in-Class T Cell Engager expected to close in the Second Quarter of 2026Following this transaction, including estimated associated R&D spend until first approval, the Company will continue to have a majority of its current cash remaining for additional strategic transactions and other capital allocation prioritiesYear-end 2026 cash and financial investments balance expected to be approximately €2BManagement to host conference call on May 7, 2026, at 14:00 CET / 8:00 am ETMechelen, Belgium; May 6, 2026, 22:01 CET; re
- SECSEC Form 6-K filed by Galapagos NV6-K - GALAPAGOS NV (0001421876) (Filer)
- PRGalapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026Mechelen, Belgium; April 28, 2026, 22:01 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG) today announces that all resolutions proposed at the Company's Annual and Extraordinary Shareholders' Meetings (AGM and EGM) held on 28 April 2026 were approved. The AGM approved, amongst other items: The Annual Report and the Remuneration ReportThe remuneration of the members of the Board of DirectorsThe appointment of Mr. Henry Gosebruch as Executive DirectorThe appointments of Dr. Jane Griffiths, Ms. Dawn Svoronos, Dr. Neil Johnston, Dr. Paulo Fontoura, and Mr. Gino Santini as Independent Non-Executive Directors and Mr. Devang Bhuva as Non-Executive DirectorThe re-appointment of the statutory auditor
- SECSEC Form 6-K filed by Galapagos NV6-K - GALAPAGOS NV (0001421876) (Filer)
- PRGalapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune DiseasesNew collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities Opportunity to develop a potential first-in-class & best-in-class T cell engager in autoimmune diseases with gamgertamig Management to host conference call today, March 31, 2026, at 14:00 CET / 8:00 am ET Mechelen, Belgium; March 31, 2026, 7.30 CET; regulated information – Announcement in application of Article 7:97, §4/1 of the BCCA — Galapagos NV ((Euronext &, NASDAQ:GLPG) ("Galapagos" or the "Company") today an
- SECSEC Form 6-K filed by Galapagos NV6-K - GALAPAGOS NV (0001421876) (Filer)
- SECSEC Form 20-F filed by Galapagos NV20-F - GALAPAGOS NV (0001421876) (Filer)
- PRGalapagos Announces Nomination of Gino Santini to its Board of DirectorsSubject to his election by shareholders, the Board intends to appoint Mr. Santini as Chair, succeeding Jérôme Contamine Mr. Santini will bring extensive corporate governance, business development and industry leadership experience to the Board Mechelen, Belgium; March 26, 2026, 21:02 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG), today announced the proposed appointment of Gino Santini as a Non-Executive Independent Director, with the intention to appoint him as Chair of its Board of Directors, subject to shareholder approval at the Annual Shareholders' Meeting (AGM) on April 28, 2026. If elected, Gino Santini will replace current Director and Chair Jérôme Contamine, whose mandate as a m
- PRGalapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders' MeetingsMechelen, Belgium; March 26, 2026, 21:01 CET; regulated information — Galapagos NV ((Euronext &, NASDAQ:GLPG) today published its annual report for the financial year 2025 and announced that its Annual Shareholders' Meeting (AGM) and an Extraordinary Shareholders' Meeting (EGM) will be held sequentially on Tuesday, April 28, 2026 at 14:00 CET and 15:00 CET at Schaliënhoevedreef 20T, 2800 Mechelen, Belgium. The annual report for the financial year 2025, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF. The annual 2025 Form 20-F filing with the SEC is available at www.sec.gov/edgar. Galapagos has t
- PRGalapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune DiseasesGalapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines New partnership structure would achieve meaningfully improved financial terms and flexibility for Galapagos Following this potential transaction, the Company will continue to have a majority of its capital available for additional strategic transactions and other capital allocation priorities Mechelen, Belgium; March 23, 2026, 23:02 CET; regulated information – inside information — Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that, following Gilead's entering into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focuse
- SECSEC Form 6-K filed by Galapagos NV6-K - GALAPAGOS NV (0001421876) (Filer)
- PRGalapagos Receives Transparency Notification from Bank of AmericaMechelen, Belgium; March 117, 2026, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Bank of America. Pursuant to Belgian transparency legislation1, Galapagos received transparency notification from Bank of America Corporation on March 12, 2026. The notification indicates that Bank of America Corporation, as controlling entity, fell below the 5% threshold for of Galapagos' voting rights on March 10, 2026, as a result of the disposal of equivalent financial instruments relating to Galapagos' voting rights. On March 12, 2026, Bank of America Corporation (taking into account the holding of its affiliates) owned 421,092 votin
- SECSEC Form 6-K filed by Galapagos NV6-K - GALAPAGOS NV (0001421876) (Filer)
- SECSEC Form 6-K filed by Galapagos NV6-K - GALAPAGOS NV (0001421876) (Filer)
- PRGalapagos Creates New Subscription Right PlanMechelen, Belgium; March 6, 2026, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announced today that its Board of Directors created 1,750,000 subscription rights under a new subscription right plan. On March 6, 2026, the Board of Directors of Galapagos approved the "Subscription Right Plan 2026", intended for personnel of the Company and its subsidiaries, within the framework of the authorized capital. Under this subscription right plan, 1,750,000 subscription rights were created for compensation of current and potential future employees. Each subscription right gives the right to subscribe to one new Galapagos share. More information can be found in the Board r
- SECSEC Form 6-K filed by Galapagos NV6-K - GALAPAGOS NV (0001421876) (Filer)
- PRGalapagos Appoints Tania Philipp as Chief Human Resources OfficerSeasoned Life Sciences Executive Joins Galapagos with Strong Track Record in Change Management Mechelen, Belgium; March 5, 2026, 22:01 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Tania Philipp as Chief Human Resources Officer (CHRO), effective March 4, 2026. Ms. Philipp will also join the Management Committee. She succeeds Annelies Missotten, who will remain with the company through June 30, 2026, to ensure a smooth transition. Ms. Philipp brings nearly three decades of experience as an executive-level human resources leader supporting the vision, mission and objectives of life sciences companies. Most recently, she served as an Executive Human Resource
- SECSEC Form 6-K filed by Galapagos NV6-K - GALAPAGOS NV (0001421876) (Filer)
- PRGalapagos Receives Transparency Notifications from Bank of AmericaMechelen, Belgium; March 4, 2026, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency legislation1, Galapagos received transparency notifications on February 27 and March 2, 2026, from Bank of America Corporation. The initial notification indicates that Bank of America Corporation, as controlling entity, and its controlled entity, BofA Securities, Inc., individually crossed above the threshold of 5% of Galapagos' voting rights on February 26, 2026, including exceeding the threshold of 5% for equivalent financial instruments, as a result of an acquisition of Galapagos' equivalen
- SECSEC Form 6-K filed by Galapagos NV6-K - GALAPAGOS NV (0001421876) (Filer)
- PRGalapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business UpdateStrategic reset positions Galapagos for long-term value creation Robust 2025 year-end cash and financial investments of €3.0 billion and ongoing collaboration with Gilead enable flexibility to execute on a business development-led growth strategy 2026 year-end cash expected to be in the range of €2.775 to €2.850 billion, with reduced cell therapy one-time restructuring cash costs of €25 million to an updated range of €125 to €175 million Management to host conference call tomorrow, February 24, 2026, at 14:00 CET / 8:00 am ET Mechelen, Belgium; February 23, 2026, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today reported its financial results for the full yea
GLPG FAQ
7 questionsWhat does Galapagos NV do?
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and...Where does GLPG stock trade?
Galapagos NV (GLPG) is listed on NASDAQ.What sector and industry is GLPG in?
Galapagos NV operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Galapagos NV go public?
Galapagos NV (GLPG) completed its IPO in 2015.What are analysts saying about GLPG?
Galapagos NV has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $4000.00 price target on 2025-10-22. Recent price targets range from $2200.00 to $4000.00.What companies are similar to GLPG?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GLPG side-by-side with any of them on Quantisnow.How can I track GLPG on Quantisnow?
Quantisnow aggregates Galapagos NV's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GLPG to receive live email and push alerts on every new disclosure.